When did it start to produce drugs?
Genentech's first-born products had to be licensed to other companies to make ends meet. Recombinant human insulin was licensed to Eli Lilly and Co. in 1982, and the clotting factor Factor VIII was licensed to Cutter Biological in 1984. The first product marketed by Genentech (and the first by any biotechnology company) was human growth hormone, which was approved for the treatment of children with growth hormone inadequacy in 1985. Other products include tissue plasminogen activator (t-PA, which dissolves the clot in heart attack patients) and DNase (which cleaves the DNA in the sputum of cystic fibrosis patients, making it less viscous and easier to remove from the lungs).
What makes Genentech's success possible?
The company has a huge investment in scaled-up production of proteins, and their main facility can put out up to 50 kg of pure protein per year. As well as this, Genentech has spent 40-50% of its revenues on research in recent years, much more than is typical for a pharmaceutical company. This emphasis on research may be shifting, however, under the scrutiny of Genentech's new owners, Roche; several senior scientists were recently made redundant.
When did Roche get involved?
Roche bought 50% of Genentech for $2 100 million in 1990, with an option to purchase the remaining shares by 1995. The deadline has now been extended to 1999; Roche currently owns 68% of Genentech. Although Genentech's management is still nominally independent, Roche's influence seems to be growing.
What's so bad about their marketing?
Genentech has been accused of encouraging the use of human growth hormone in children who are only normally short, not growth-hormone deficient -a charge that the company naturally denies. And there has been considerable controversy over the question of whether t-PA, a costly human protein produced in mammalian cell culture, is in fact any more effective than a bacterially derived product, streptokinase, which costs a tenth of the price. A huge trial recently showed that streptokinase was good, but t-PA was better.
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Immune surveillance and AIDS progression Rolf Zinkernagel and Paul Klenerman
In their recent Dispatch [1] , Mark Feinberg and Angela McLean rightly point out that there have been two unproven assumptions about human immunodeficiency virus-1 (HIV-1) pathogenesis: that cytotoxic (CD8) T lymphocyte (CTL) activity is important in regulating viral load, and that failure of this activity leads to loss of viral control and progression to AIDS. They themselves, however, make two further assumptions about this disease: that the virus itself is responsible for the death of infected cells, and that any CTL-mediated killing should limit, rather than promote, death of helper T cells.
It is important to consider the possibility that HIV infection in man causes cell and tissue destruction not directly, but indirectly via the induced immune response [2] . Although HIV-1 isolates may cause cell destruction in vitro, this has yet to be morphologically demonstrated in vivo. Lymphocytic choriomeningitis virus (LCMV) may also cause cytopathic effects in cultured cells, but is a clear example of a virus which is non-cytopathic in vivo in its natural hosts (mouse and hamster) [3] . In addition, the development of CTL escape mutants that has been documented in HIV-1 [4] , has only been observed elsewhere in viruses that are non-cytopathic in their respective hosts, notably LCMV, Hepatitis B virus (HBV) and human T-cell leukemia virus-1 [5] [6] [7] . Finally, although cytopathic viruses induce a very rapid neutralizing antibody response, non-cytopathic viruses may fail to do so. In this respect, HIV-1 follows the pattern of HBV and LCMV, where neutralizing antibody arises 60-150 days after infection, at a time when most of the virus has been cleared [8] . For LCMV this delay may be ascribed to a sophisticated virus-host relationship: B cells producing neutralizing antibody, but not B cells producing antibodies specific for viral internal proteins, are infected early by virus, and become targets for lysis by virus-specific CTL [8] . This mechanism, which facilitates long-term viral persistence, may apply in HBV and HIV-1.
Although LCMV itself is noncytopathic in vivo, it may, like HIV-1, induce a state of immunosuppression [9] . In the mouse, this is mediated by antiviral cytolytic CD8 T cells, but various soluble factors, including tumour necrosis factor and interferon γ may also be involved in this immunopathology -observed histologically as destruction of antigen-presenting cells and follicular architecture [10, 11] .
The overall outcome, even in this relatively simple system, is highly variable, and point mutations in the viral genome that alter growth rate or tropism may have a huge effect. At the one extreme, an early and efficient CTL response may lead to low viral loads and little immunopathology, whereas at the other a state of high viral load and immunological tolerance may be observed. Between these two, a combination of widespread virus and active CTL responses can lead to a progressive immune-mediated pathology within the lymphoid system itself. Thus, the same CTL response may be protective, destructive or apparently totally ineffective, depending on the dose, kinetics of growth and distribution of the virus. The practical implications of this are that boosting CTL activity at a time of high viral load may cause enhancement of disease, and that such CTL responses might also render induction of protective neutralizing antibody responses difficult, through lysis of B cells.
At the conclusion of their article, the authors consider two possibilities: that progression to AIDS has little to do with failure of immune surveillance, and that clearance of infected cells has little to do with CTL activity, at least as it is currently measured. Perhaps we should add a third possibility, that CTL-mediated killing may contribute to both immune surveillance and clearance of infected cells in vivo, but that the outcome may be very finely balanced, as illustrated by LCMV infection of the mouse. We concur with their suggestion that the specific anti-HIV-1 CTL response may have indirect consequences for the host, perhaps contributing to an as yet unquantified degree of CD4 T-cell loss, and potentially giving rise to AIDSassociated conditions such as wasting and dementia. We also agree that a better understanding of the balance that determines whether host antiviral immune responses are beneficial or detrimental is needed (Fig. 1) . But although the potential indirect consequences of HIV-1 infection represent an important topic for further study, we believe strongly that the weight of evidence indicates that HIV-1 is, in fact, a cytopathic virus that can cause direct destruction of CD4 T cells both in tissue culture and in vivo. Thus, at least in the context in which it is raised, we question the notion that LCMV is a valid model for understanding the immunopathogenesis of HIV-1 infection.
It is difficult to prove that a virus is directly cytopathic in vivo, particularly if infected cells are killed and cleared rapidly. Although the appearance of multinucleated giant cells (syncytia) is taken as evidence of the in vivo cytopathic effects of herpes virus infections, this is certainly not the only mechanism by which viruses can induce cell death. Indeed, syncytia have been seen in lymphoid tissues and in the central nervous system of HIV-1-infected persons, although they are rare [2, 3] .
We believe that there is stronger evidence for the direct (nonimmunologically mediated) cytopathic effects of HIV-1 infection. As discussed in our Dispatch [1] , HIV-1-infected cells live for only a short period of time, there is little variability between hosts in their rate of clearance, and there is no association between the lifespan of R404 Current Biology, Vol 7 No 7 infected cells and the host's immunocompetence, as assessed by CD4 T-cell count. Furthermore, the appearance of HIV-1 variants with more dramatic cytopathic consequences in tissue culture infections is associated with more rapid decline in CD4 T-cell counts in vivo, even though these typically appear when immune function is already substantially compromised [4] .
Perhaps the best evidence against the suggestion of Drs Zinkernagel and Klenerman comes from studies of infants who are infected with HIV-1 at or near the time of birth. Such perinatally-infected children display extremely high levels of HIV-1 replication (evidenced by high plasma HIV-1 RNA levels), and often progress to AIDS within the first year or two of life. Perhaps as a result of the immaturity of their immune systems or the induction of tolerance to HIV-1 in the setting of neonatal exposure, perinatallyinfected infants often do not mount detectable anti-HIV-1 CTL responses. When they do so, it is typically not until 6-12 months after birth, a time when profound immune deficiency is already manifest. By contrast, in the LCMV model, where the virus is non-cytopathic, neonatal infection of mice leads to the induction of immunologic tolerance, high levels of chronic viremia, and the absence of disease [5] .
To address the balance between beneficial and detrimental immune responses discussed by Drs Zinkernagel and Klenerman, we used a simple mathematical model ( Figure  1 ). During infection, the killing of infected cells has two effects, on one hand giving rise to fewer infected cells, while on the other (through reducing further rounds of infection) giving rise to more uninfected cells. The effect on the total number of cells is therefore complex and hard to predict from intuition alone.
Standard models of in vivo infectious processes can aid in understanding this apparent complexity. They reveal that the balance between beneficial and detrimental effects of immune killing of infected cells is strongly conditioned by the magnitude of the cytopathic effect of the virus itself. There are three classes of outcome: for totally non-cytopathic viruses, immunopathology is always detrimental; for viruses of intermediate cytopathicity, the immune-mediated killing of infected cells must exceed a certain threshold before it is beneficial; and for highly cytopathic viruses, any killing of infected cells is beneficial. As the vast weight of evidence indicates that HIV-1 can kill infected cells in vivo, it must fall into the second or third group. LCMV, being non-cytopathic falls into the first class and may, therefore, not be the best available model for immunopathology in HIV-1 infection. 
